- Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and moreWelcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...Endpoints · 3mo ago↗ source
- FDA unveils three psychedelic-focused commissioner vouchersThe FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street. In an unusual move, the agency didn’t name t…Endpoints · 3mo ago↗ source
- Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drugAvalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…